IMR Press / CEOG / Volume 39 / Issue 4 / pii/1630475815184-1361742889

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Editorial
Luteal phase support for in vitro fertilization-embryo transfer – present and future methods to improve successful implantation
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology Division of Reproductive Endocrinology & Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2012, 39(4), 422–428;
Published: 10 December 2012
Abstract

Purpose: To present reasons for luteal phase deficiency when taking controlled ovarian hyperstimulation (COH) for purposes of inducing multiple oocytes for in vitro fertilization (IVF), and to suggest strategies to overcome the defect. Methods: Treatment options presented include luteal phase support with human chorionic gonadotropin (hCG) injection, progesterone, estradiol, gonadotropin releasing hormone agonists, cytokines, e.g., granulocyte colony stimulating factor, and lymphocyte immunotherapy. Results: hCG and progesterone produce the best results and are comparable or at best a slight edge to hCG but the latter is associated with too high a risk for ovarian hyperstimulation syndrome. Vaginal progesterone is the most efficacious with the least side-effects. Conclusions: Better methods are needed to adequately assess full correction of the luteal phase defect. In some cases the luteal phase defect associated with COH is not correctable and FSH stimulation should be reduced or all embryos frozen and defer transfer to an artificial estrogen progesterone or natural cycle.
Keywords
Progesterone
Controlled ovarian hyperstimulation
Human chorionic gonadotropin
Estradiol
Gonadotropin releasing hormone agonist
Share
Back to top